Clinical trial NCT05373888: Safety and Performance of Flexima®/Softima® Stoma Appliances in Enterostomy Patients
Official title: Prospective, Non-interventional, Post-Market Clinical Follow-up Investigation of the Safety and Performance of Flexima®/Softima® Stoma Appliances in Enterostomy Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Enterostomy
Stoma Ileostomy
Stoma Colostomy
Keywords: enterostomy
colostomy
ileostomy
stoma
jejunostomy
stoma appliance
Lead sponsor: BBraun Medical SAS
Sponsor class: INDUSTRY
First posted: 2022-05-13
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Enterostomy patients, including colostomates, ileostomates or jejunostomates.

Brief summary: The study is designed as a non-interventional, prospective, international, multi-center, post market follow-up investigation. The product under investigation will be used in routine clinical practice and according to Instructions for Use (IFU). The data obtained during routine clinical use will be documented in electronic Case Report Forms (eCRF).

The investigation will consist of an enrolment visit (Visit 1, or V1) and a final visit (Visit 2, or V2). The duration between the two visits is 14 (±3) days.

Detailed description: Details of the procedures performed at each visit follow.

#A ENROLMENT VISIT (Visit 1, onsite)

The following procedures will be performed:

* Informed consent
* Eligibility assessment
* Record demographics
* Record medical and surgical history (including stoma details)
* Record details of the appliance currently used, which could be different than a Flexima®/Softima®. However, participation in the investigation requires a Flexima®/Softima® appliance be used.
* Peristomal skin assessment (DET scoring)
* Discuss investigation requirements with the participant, including the need of adequately completing the patient's diary
* Start recording adverse events and concomitant medications

  * B 14 (±3 DAY) DEVICE WEARING TIME (telephone follow-up)

During the wearing time, the following procedures will be done:

* The clinical site personnel will follow-up with the participants by telephone as required
* Participants will complete the patient's diary, which includes a record of appliance changes and assessment of leakages
* Record adverse events and concomitant medications (via telephone follow-up)

  * C FINAL VISIT (Visit 2, onsite)

During the final visit, the following procedures will be done:

* Peristomal skin assessment (DET scoring)
* Participant evaluation of device performance (see 8.2.7)
* The responsible site personnel will review the patient's diary together with the patient. Any missing data will be discussed with the patient and, if possible, completed. In case it can't be completed, clarification notes explaining the reason for the missing data are to be added to the patient's diary (e.g. details forgotten)
* Record adverse events and concomitant medications

Eligibility criteria: Inclusion Criteria:

* Patients for whom the use of a Flexima®/Softima® appliance is indicated and has been decided within the regular planning of their treatment. Both, new users or users already using Flexima®/Softima® appliances are eligible for participation.

Exclusion Criteria:

* Patients under 18 years old
* Patients who are mentally or linguistically unable to understand the aim of the investigation; or unable to comply with the investigation procedures.
* Patients taking part in another clinical investigation which could have an impact on the current investigation.
* Patient vulnerable. Vulnerable patients are adults unable to express their consent, patients under legal protection, patients deprived of their liberty by a judicial or administrative decision, patients subject to psychiatric care against their will and pregnant, parturient or breastfeeding women.

Primary outcomes:
measure: Number of patients with at least one adverse device effect (ADE) as judged by the clinician.
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Fundacion Jimenez Diaz
Study officials:
References: